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Elimination of a disease sounds attractive, but as the recent
re-emergence of polio has shown, it is difficult to accomplish.
As part of its roadmap for reducing the burden of neglected
tropical diseases, the World Health Organization has identified
five diseases for elimination by 2015 and a further eight by
2020.1Although setting these ambitious targets has the potential
to focus money and resources, unless the targets are realistic
they can have unforeseen consequences.We use the experience
of the 1991 campaign to eliminate leprosy to show how targets
can end up causing harm to patients.
Why choose leprosy?
Leprosy is a stigmatising and potentially disabling disease.
Despite the introduction of an a global treatment programme in
the 1980s around 230 000 cases are diagnosed annually, mainly
in India and Brazil but also in 41 other countries.2 Leprosy is
caused byMycobacterium leprae and is spread through droplets.3
However, the disease can be treated with a six or 12 month
course of multidrug therapy (rifampicin, dapsone, and
clofazimine), which has a cure rate of 98%.4 The condition can
be diagnosed clinically by recognising a range of characteristic
skin lesions and palpating thickened peripheral nerves (box 2).
Diagnosis can be confirmed through detection of acid fast bacilli
in slit skin smears or through granulomatous inflammation in
skin and nerve biopsy samples.5 Up to 60% of patients have
peripheral nerve damage at diagnosis, which requires treatment
with steroids lasting several months.6 7 Even after effective
treatment long term morbidity can be problematic; immune
mediated complications can occur for years and education and
monitoring are needed to prevent damage to hands, feet and
eyes in those with peripheral neuropathy.7
After aWHO expert committee on leprosy recommended fixed
duration antibacterial multidrug therapy for leprosy patients in
1982,8 it was postulated that effective treatment would interrupt
transmission globally, and in 1991 the World Health Assembly
passed a resolution to “eliminate leprosy as a public health
problem by the year 2000.”
What does elimination mean?
The target for elimination of leprosy (and other diseases) as a
public health problem did not mean achieving a prevalence or
incidence of zero. For leprosy WHO set a target to achieve a
prevalence of less than one case per 10 000 population at a
global level.9 The selection of this number was arbitrary and
not supported by mathematical modelling of leprosy data.10
WHO’s leprosy unit in Geneva monitored the elimination
programme, with programme managers in endemic countries
required to report annual leprosy figures for publication.
Reality of eliminating a disease
The leprosy elimination strategy had strengths. It committed
governments, donors, and health workers to focus on leprosy11
and facilitated free drug treatment.12 Diagnosis was simplified
with a straightforward field based classification based on
counting the number of skin lesions13 and new case detection
was promoted with innovative approaches.14 Mass detection
campaigns were held to detect early cases and special
progrmammes were set up to detect cases in nomadic
populations.
However, India and Brazil, two countries with high prevalences
of leprosy, provide case studies of how the elimination target
had unintended consequences. In India from 1983 there was an
energetic campaign supported by the Indian government and
leprosy non-governmental organisations, which had the initial
effect of increasing detection rates. Despite efforts to clean the
leprosy register by removing patients who had completed
antibacterial treatment, many of whom had chronic
complications, India failed to meet the 2000 target and the date
for elimination was moved to 2005. In order to help meet this
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Box 1: Neglected tropical diseases identified by WHO for elimination1
By 2015
• Rabies in Latin America
• Chagas disease transmission through blood
• Human African trypanosomiasis in selected countries
• Onchocerciasis in Latin America
• Schistosomiasis in Eastern Mediterranean region, Caribbean, Indonesia, and Mekong river
By 2020
• Rabies in South East Asia and Western pacific
• Blinding trachoma
• Leprosy
• Chagas in most Latin American countries
• Human African trypanosomiasis
• Visceral leishmaniasis in Indian subcontinent
• Lymphatic filariasis
• Endemic treponematoses (yaws)
Box 2: Case definition for leprosy (WHO, 2012)
Presence of one of the following:
• Loss of sensation in pale or reddish skin lesions
• Peripheral nerves with loss of sensation or weakness of the muscles supplied by that nerve
• Acid fast bacilli in a slit skin smear sample
target the country moved to voluntary reporting and stopped
actively seeking new cases and screening contacts (box 3).
Detection rates fell by 75% between 2003 and 2005 (fig 1⇓).
Although India met the 2005 target, many players questioned
the reported leprosy figures, and independent studies showed
many undiagnosed patients. Leprosy patients petitioned the
Indian parliament about post-elimination services. The
government commissioned a national sample survey of 15
million people in 2010, which had a case detection rate of 2.57
per 10 000. The survey findings have not yet been published
nor mentioned on the website. In 2011 India reported 127 509
new cases.18 The difference between the reported and observed
estimates suggests that up to half of India’s leprosy cases are
not being reported. India has been reporting about 130 000 new
cases a year (fig 1⇓), which keeps it safely in the eliminated
leprosy category. There is therefore no incentive to find new
cases.
After closing its leprosy colonies in the 1970s and integrating
leprosy services into primary care, Brazil was already making
progress in reducing the disease. It adopted theWHOmultidrug
treatment regimen in 1991 and established referral centres
integrated with dermatological services.19A successful research
programme was also set up, funded by the WHO Immunology
of Leprosy Project. New case detection continued at a steady
rate, and this should have been congratulated (fig 2⇓).20
However, the programme was under pressure to show progress
towards elimination, and the 2004 returns omitted patients
detected during October to December 2004 because they were
not yet registered.19 This enabled Brazil to achieve elimination
in 2005, but this was retracted when the missing patients were
reinstated (box 4).18 The under-reporting of cases resulted in a
shortage of drugs for treatment of new patients.
The country is again under pressure to reach the elimination
target. Yohei Sasakawa, chairman of the Nippon Foundation,
which funds theWHO elimination programme, announced that
the country would reach the target at a Brazilian leprosy
conference in October 2011.21Academics in Brazil felt that they
were being pressured, and this announcement was widely
discussed on the web based leprosy mailing list (http://
leprosymailinglist.blogspot.co.uk/).
Globally, the leprosy elimination campaign contained an
inherent problem because it was assumed that transmission
would drop when case detection and treatment were widened.
The possibility that this might not happen in some countries
was not considered. New case detection rates in both India and
Brazil showed evidence of ongoing transmission into the 21st
century (figs 1⇓ and 2⇓).22 However, both programmes were
pressed to meet the target of leprosy elimination by WHO and
the Nippon Foundation. This could be done only by reporting
fewer patients. The Indian programme adopted measures that
ensured that fewer patients were registered, including not
registering single lesion cases and no tracing of household
contacts, even though this is not good public health practice.16
These changes led to patients being undiagnosed17 and
experiencing important delays in starting treatment.23
Damage from chasing a target
Leprosy was an inappropriate disease to choose for elimination.
The biology of leprosy means that it is not suitable for an
elimination target within 10 years. The incubation period is
long—2-15 years depending on the type of leprosy3—so new
patients can continue to present for many years after successful
control campaigns have ended. South Africa attained elimination
rates in 1926 but new cases still present today.24 Modelling of
the leprosy elimination strategy based on trends in case detection
rates for 1995-8 predicts that it will slow transmission but that
complete elimination will take decades to achieve.25
Obsession with the leprosy target caused schisms in the leprosy
world. Leprosy non-governmental organisations were asked to
leave the Global Alliance for the Elimination of Leprosy, which
meant that the organisations that lead work nationally had no
input to global leprosy health policy.
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Box 3: India: Strategies for leprosy control and elimination as a public health problem, 1983-2012
1983:Government establishes a national leprosy eradication programme with strategy of early detection of cases by surveys and contact
examination and treatment with multidrug regimen
1996-7: Fixed duration treatment introduced with “cleaning” of registers and patients not on treatment removed from the list. New case
detection rate 4.6/10 000
1997: Campaigns to reach undetected cases initiated
1998: Modified leprosy elimination campaigns launched emphasising public awareness and voluntary reporting of patients. One million
new cases were detected in five campaigns
1999: New case detection peaked at 8.9/10 000
2000: India did not meet elimination target because the national prevalence was 5.2/10 000
Altered strategy to reach elimination target
2000: WHO proposes “final push” and moves target date to 200515
2002: National health policy set the goal for leprosy elimination by 2005 and national detection rate began to fall 25% a year (fig 1⇓)
2004: Leprosy services moved into general healthcare services with large scale staff training. Voluntary reporting of patients became
the main strategy
2005: WHO Kathmandu produced policy directives to reduce prevalence, which included the following16:
• Stop all active searches for new case detection.
• New cases to be given multidrug treatment only after validation by authorities locally
• Delete names of the patients from the register as they receive the last dose of treatment
• Do not register single lesion leprosy cases
• Cease screening household contacts
2005: India achieved elimination nationally
2007: Independent surveys in Maharashtra show cases levels of 2.96-9.52/10 00017
2009: National Forum of Leprosy Patients petitioned parliament to investigate the numbers of leprosy patients
2010: National sample survey of 15 million people examined detects 2177 cases. Weighted new cases rate estimated at 2.5/10 000
with 11.2% with visible deformities (WHO grade 2 disability). Results not yet released to public
Box 4: Strategies for leprosy control and elimination as a public health problem in Brazil, 1980-2013
1980: Leprosy clinics established in general health service clinics and health surveillance started
1991: WHO multidrug regimen adopted as treatment in national leprosy programme
2000: Stable numbers of new leprosy patients in Brazil, with small increase year on year
2005: Brazil reached elimination target, 38 423 leprosy patients were registered. This was achieved by omitting the patients registered
in the last quarter of 2004. The final figure was corrected to 51 000 patients (June 2005).18
2006: Shortage of drugs because of under-reporting of case numbers
2007-10: Slow fall in incidence and a slight rise in prevalence, and Brazilian government made diplomatic efforts to revise the WHO
leprosy elimination target.
2010: National guidelines issued for care, surveillance, and control of leprosy in primary care
2010: 90% of leprosy patients receiving treatment in primary care
2000-11: Decentralisation of leprosy control with big increase (283%) in the number of health units treating leprosy patients
2011: Leadership of Brazilian Health Surveillance changed and elimination as a public health problem again became a target
2013: Discussions about the possibility of leprosy elimination in 2015 resumed
In 2007 WHO abandoned the elimination target for leprosy
programme and instead set a target based on disability rates
with the aim of improving focus on prevention of disability.26
Despite the shift in emphasis WHO still reports global leprosy
rates and which countries have achieved elimination. Political
commitment to leprosy has been lost. Funding and support for
leprosy agencies have been declining at 5% a year for the past
five years (International Federation of Anti-Leprosy
Associations (ILEP), personal communication). Skills in
diagnosing and managing leprosy have also been lost as
programmes have been left unsupported.27 This has also been
accelerated by the transfer of diagnosis and management of
leprosy to peripheral health workers in many countries, away
from specialist centres. The rhetoric on elimination has
discouraged dermatologists from engaging with leprosy
programmes, even though they may be diagnosing cases in the
private sector, because they believe leprosy is eliminated.19
Academic work on leprosy has declined; it rarely figures in
medical school curriculums even in endemic countries, and
research has declined.28 29 Young researchers perceive that the
disease is eliminated. The International Journal of Leprosy
ceased publication in 2005 with an editorial noting the absence
of scientific evidence for the elimination policy.30
Future of elimination
The terminology of leprosy elimination was confused and
misleading. Many people, from policy makers to observers,
understood the goal to be complete elimination rather than
reduced prevalence. It is important in future that those involved
in campaigns, politicians, funders, health services, and the wider
media are clear about what elimination means. AlthoughWHO
has defined the terms “eradication,” “elimination,” and
“elimination as a public health problem,” the possibility of
confusion remains, and the terms could be misused for political
purposes (box 5).31 32
Elimination of any disease is a powerful target and sets high
expectations. Targets used judiciously can energise programmes,
and the leprosy campaign reached out to many countries and
ensured that millions of patients were detected and cured and
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Box 5: WHO definitions of elimination1
Control—Reduction of disease incidence to a locally acceptable level
Elimination—Reduction of the incidence of infection to zero
Eradication—Permanent worldwide reduction of infection to zero
gave leprosy a much higher profile. However, this achievement
has been lost in the retrenching that has been required to take
forward planning for a chronic disease. The lessons of leprosy
show that monitoring of targets must be transparent. Workers
strive to reach targets and find unexpected ways of doing so,
particularly if incentives or pressure is exerted on them. This
mirrors the use of targets elsewhere—for example, in the English
NHS where targets can disrupt the focus of services.33
A target to eliminate should be set only if it is realistic. The
following conditions are needed: straightforward diagnosis,
effective treatment, low transmissibility, and ability to
differentiate between current and past infection. Of the diseases
listed for elimination on theWHO roadmap only rabies in Latin
America fulfils these conditions.
When it was clear that leprosy transmission continued in many
countries the appropriate response should have been to redefine
the campaign rather than cling on to it. It is important to learn
the lessons from earlier elimination programmes.34 Targets need
to be evidence based. Like a battle strategy, they need to be
reviewed regularly and amended when inappropriate.
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Figures
Fig 1 Incidence and prevalence of leprosy in India, 1991-2011 (data from Weekly Epidemiological Record)
Fig 2 Leprosy prevalence and detection rates in Brazil, 1990-2010 (data from Brazilian Ministry of Health)
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